Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q03393
UPID:
PTPS_HUMAN
Alternative names:
-
Alternative UPACC:
Q03393; B0YJ87; Q8WVG8
Background:
6-pyruvoyl tetrahydrobiopterin synthase plays a pivotal role in the biosynthesis of tetrahydrobiopterin (BH4), a critical cofactor for aromatic amino acid hydroxylases. This enzyme catalyzes the conversion of 7,8-dihydroneopterin triphosphate into 6-pyruvoyl tetrahydropterin, facilitating neurotransmitter production.
Therapeutic significance:
The enzyme's deficiency is linked to Hyperphenylalaninemia, BH4-deficient, A, a disorder marked by cognitive and motor deficits due to neurotransmitter depletion. Targeting this protein could lead to novel treatments for this autosomal recessive disease.